August 30, 2010 — It is estimated that approximately 500,000 infections caused by Clostridium difficile occur in hospitals in the United States each year. And, according to the Centers for Disease Control and Prevention, C. diff infection rates are on the rise throughout the U.S., with emerging antibiotic-resistant strains and increased mortality rates.
Additionally, the infection is taking longer to resolve, with many patients experiencing multiple relapses and requiring prolonged treatment, as noted in an Aug. 24 story in the Washington Post.
Dr. William A. Petri Jr. of the University of Virginia, an authority on C. diff, is available for media interviews. He and research colleagues have identified a novel way to prevent, treat and diagnose C. diff infection through a specific biomarker.
Petri is a professor of infectious diseases and international health at the U.Va. School of Medicine. He holds nearly a dozen patents based on his research.
To arrange an interview, contact Glenn Glover, 434-243-9552, gmg6n@virginia.edu.
Additionally, the infection is taking longer to resolve, with many patients experiencing multiple relapses and requiring prolonged treatment, as noted in an Aug. 24 story in the Washington Post.
Dr. William A. Petri Jr. of the University of Virginia, an authority on C. diff, is available for media interviews. He and research colleagues have identified a novel way to prevent, treat and diagnose C. diff infection through a specific biomarker.
Petri is a professor of infectious diseases and international health at the U.Va. School of Medicine. He holds nearly a dozen patents based on his research.
To arrange an interview, contact Glenn Glover, 434-243-9552, gmg6n@virginia.edu.
Media Contact
Article Information
August 30, 2010
/content/tipsheet-c-diff-new-superbug-uva-expert-available-interviews